Secukinumab Lowers Expression of ACE2 in Affected Skin of Patients With Psoriasis.
2020
Capsule summary (33 of 35 words; 2 of 2 sentences): Secukinumab reduced the inflammation and the expression of ACE2, which encodes the SARS-CoV-2 receptor, in plaques of patients with psoriasis. Reductions in ACE2 expression with secukinumab significantly correlated with reductions in disease activity.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
10
References
6
Citations
NaN
KQI